

Chronic myelomonocytic leukaemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/C5867937FA6DEN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: C5867937FA6DEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Chronic myelomonocytic leukaemia - Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic myelomonocytic leukaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic myelomonocytic leukaemia Understanding

Chronic myelomonocytic leukaemia: Overview

Chronic myelomonocytic leukaemia (CMML) is a form of leukaemia that is characterised by high numbers of white blood cells, called 'monocytes', in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a 'mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)'. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets). MDS is a group of diseases that affects, to a greater or lesser

extent, the production of normal blood cells in the bone marrow.

'Chronic myelomonocytic leukaemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic myelomonocytic leukaemia pipeline landscape is provided which includes the disease overview and Chronic myelomonocytic leukaemia treatment guidelines. The assessment part of the report embraces, in depth Chronic myelomonocytic leukaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic myelomonocytic leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic myelomonocytic leukaemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic myelomonocytic leukaemia.

Chronic myelomonocytic leukaemia Emerging Drugs Chapters

This segment of the Chronic myelomonocytic leukaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic myelomonocytic leukaemia Emerging Drugs

Sabatolimab: Novartis Oncology

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic myelomonocytic leukaemia.

Enasidenib: Servier

Enasidenib (AG 221) is a small molecule, oral inhibitor of isocitrate dehydrogenase 2 (IDH2), being developed by Servier. The drug is currently in phase I stage of development for the treatment of Chronic myelomonocytic leukaemia.

Further product details are provided in the report.....

Chronic myelomonocytic leukaemia: Therapeutic Assessment

This segment of the report provides insights about the different Chronic myelomonocytic leukaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic myelomonocytic leukaemia

There are approx. 25+ key companies which are developing the therapies for Chronic myelomonocytic leukaemia. The companies which have their Chronic myelomonocytic leukaemia drug candidates in the most advanced stage, i.e. phase III include, Novartis Oncology.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic myelomonocytic leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic myelomonocytic leukaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic myelomonocytic leukaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic myelomonocytic leukaemia drugs.

Chronic myelomonocytic leukaemia Report Insights

- Chronic myelomonocytic leukaemia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Chronic myelomonocytic leukaemia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic myelomonocytic leukaemia drugs?

How many Chronic myelomonocytic leukaemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic myelomonocytic leukaemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic myelomonocytic leukaemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic myelomonocytic leukaemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis Oncology

Servier

Eltrombopag

Immune-Onc Therapeutics

H3 Biomedicine

Chroma Therapeutics

Nerviano Medical Sciences

Astex Pharmaceuticals

Takeda Oncology

Argenx

Kura Oncology

Incyte Corporation

Genentech, Inc.

Sensei Biotherapeutics

Pfizer

BioLite, Inc.

Newave Pharmaceutical Inc

Ellipses Pharma

Eli Lilly and Company

Aprea Therapeutics

Treadwell Therapeutics

Prelude Therapeutics

Onconova Therapeutics

Immune Pharmaceuticals

Teva Pharmaceutical Industries

Key Products

Sabatolimab

Enasidenib

IO 202

H3B 8800

Tefinostat

NMS 03592088

Guadecitabine

Pevonedistat

Cusatuzumab

Tipifarnib

Ruxolitinib

Venetoclax

SNS-301

Cobimetinib

Glasdegib

BLEX 404

LP-108

Canakinumab

EP0042

LY3410738

APR-246

CFI-400945

PRT543

Rigosertib

Histamine dihydrochloride injection

Arsenic trioxide

Contents

- Introduction
- Executive Summary
- Chronic myelomonocytic leukaemia: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Sabatolimab: Novartis
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Tefinostat: Chroma Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- Enasidenib: Servier
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Chronic myelomonocytic leukaemia Key Companies

Chronic myelomonocytic leukaemia Key Products

Chronic myelomonocytic leukaemia- Unmet Needs

Chronic myelomonocytic leukaemia- Market Drivers and Barriers

Chronic myelomonocytic leukaemia- Future Perspectives and Conclusion

Chronic myelomonocytic leukaemia Analyst Views

Chronic myelomonocytic leukaemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Chronic myelomonocytic leukaemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Chronic myelomonocytic leukaemia

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Chronic myelomonocytic leukaemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C5867937FA6DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5867937FA6DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970